health · HHS-NIH11

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

National Institutes of Health · RFA-CA-27-001

82 days left

Award Range

$0 – $150K

Total Program Funding

$5.1M

Expected Awards

Deadline

November 10, 2026

GRANTQUICK SUMMARYPlain-English Overview

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed). National Institutes of Health. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of... up to $150,000 per award; $5,100,000 total program funding; ~20 awards expected.

Who Should Apply

Other Native American Tribal Organizations, Federally Recognized Native American Tribal Governments, Nonprofits (non-501c3), For-profit organizations, State governments (+10 more)

Who Should NOT Apply

Organizations not matching the eligible applicant types listed above

Key Requirements (Plain English)

•Refer to Section III
•Deadline: 2026-11-10

💡 GrantQuick Tip

Clearly demonstrate alignment with funding priorities and provide measurable outcomes.

Competitiveness: High — limited number of awards

What This Grant Funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Attachments

PDF

RFA-CA-27-001-Full-Announcement.html

Who Can Apply

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Eligible Applicant Types

Other Tribal OrganizationsFederally Recognized Tribal GovernmentsNonprofits without 501(c)(3)For-Profit OrganizationsState GovernmentsSpecial District GovernmentsPublic Colleges & UniversitiesSmall BusinessesCounty GovernmentsPublic And Indian Housing AuthoritiesCity/Township GovernmentsOther (see NOFO for details)Private Colleges & Universities501(c)(3) NonprofitsIndependent School Districts

Funding Details

Maximum Award: $150K
Total Program Funding: $5.1M
Expected Number of Awards: 20
Cost Sharing Required?: No
Funding Instrument: grant

Key Dates

Posted: June 3, 2026

Application Deadline: November 10, 2026 (82 days remaining)

Agency Contact

National Cancer Institute (NCI) Kelly.crotty@nih.gov

Kelly.crotty@nih.gov

Ready to apply?

View the full NOFO and submit your application on Grants.gov

View on Grants.gov